Versigent (VGNT) investor relations material

Executive summary

• Q3 net sales rose 7.2% YoY to $2.45B; adjusted net sales growth, excluding commodity and FX movements, was ~1%.

• Adjusted EBITDA increased 10.9% to $275M, with margin up 40 bps to 11.2%, despite lower global automotive production and heavy launch activity.

• Q3 bookings were $2.1B; FY26 net sales and free cash flow guidance midpoints increased, while the Adjusted EBITDA range narrowed with its midpoint unchanged.

Financial highlights

• Q3 net sales were $2.45B versus $2.286B; reported growth included ~500 bps from commodity pass-throughs and ~100 bps from favorable FX.

• Adjusted EBITDA was $275M versus $248M; Adjusted EBITDA margin was 11.2% versus 10.8%.

• Net income attributable was $102M versus $109M; diluted EPS was $1.41 and Adjusted diluted EPS was $1.91 versus $1.81.

• Free cash flow was $170M versus $179M; higher capital expenditures, interest, cash taxes, and separation costs weighed on the comparison.

Outlook and guidance

• FY26 net sales guidance is $9.5B–$9.6B, up from $9.4B–$9.6B; adjusted net sales growth remains ~2%, with the increase driven by copper pass-throughs.

• FY26 Adjusted EBITDA guidance is $970M–$1.01B versus $950M–$1.03B previously; the midpoint remains $990M and both ranges include $70M of separation costs.

• FY26 free cash flow guidance increased to $275M–$325M from $200M–$300M; the midpoint rose $50M to $300M, partly due to initiatives shifting into 2027.

• The 2026–2028 cumulative free cash flow target remains ~$1B; FY26 outlook implies ~30 bps of Adjusted EBITDA margin expansion versus 2025.